Viking Therapeutics Q2 Loss Widens on Surging R&D; New ATM and $500M Buyback Authorized

summarizeSummary

Viking Therapeutics reported a wider Q2 loss on soaring R&D costs, replaced its ATM program, and authorized a larger $500 million buyback, while announcing executive changes and advancing its obesity pipeline.

check_boxKey Events · Earnings and Guidance · VKTX

• Q2 Loss Widens on R&D Surge

  Net loss of $128 million vs. $65.6 million a year ago, as R&D expenses jumped 92.4% to $115.8 million, primarily for Phase 3 obesity trials VANQUISH-1 and VANQUISH-2.

• Cash Runway into Late 2027

  Cash, equivalents, and short-term investments totaled $501.9 million at June 30, 2026, down from $705.7 million at year-end 2025, but sufficient to fund operations through at least September 2027.

• New ATM and Upsized Buyback

  Entered into a new at-the-market equity offering sales agreement on July 29, 2026, replacing the prior ATM, and authorized a new $500 million stock repurchase program, up from the prior $250 million program.

• COO Retirement and Board Appointment

  COO Marianne Mancini will retire effective July 31, 2026; Dorothy Kelly-Gemmell appointed to the board effective August 1, 2026, bringing commercial and healthcare experience.

auto_awesomeAnalysis · VKTX · Life Sciences

Viking's Q2 net loss more than doubled to $128 million as R&D spending jumped 92% to $115.8 million, driven by Phase 3 obesity trials. The company ended the quarter with $502 million in cash and investments, providing runway into late 2027. Simultaneously, Viking replaced its expiring ATM with a new at-the-market facility and upsized its stock repurchase authorization to $500 million. The COO is retiring, and a new director with commercial experience joins the board. These moves come amid an ongoing legal dispute with Ligand Pharmaceuticals over the VK2809 license, adding uncertainty to the NASH program.